Science Corporation implants vision-restoring chip in first Stargardt disease patient

Science Corporation has announced the successful implantation of its vision-restoring chip into its first patient diagnosed with Stargardt disease. The company's CEO, Max Hodak, formerly president and co-founder of Neuralink, shared the news during the TechCrunch Disrupt technology conference.

This procedure represents a significant milestone in the development of the company's brain-computer interface (BCI) technology, aimed at assisting individuals with vision impairment. Stargardt disease is a common inherited eye condition that affects central vision, leading to progressive vision loss.

The chip, also referred to as PRIMA, is progressing as planned according to company statements. Science Corporation's objective is to provide novel therapeutic solutions for visual impairment by establishing a direct link between the brain and external devices.

Further details regarding the specifics of the implantation's outcomes or the patient's current condition have not yet been disclosed. Hodak indicated that the company's focus will now shift to continuing clinical trials and further validating the technology's performance.